MotzerR.J., HutsonT.E., TomczakP., MichaelsonM.D., BukowskiR.M., RixeO., OudardS., NégrierS., SzczylikC., KimS.T., ChenI., BycottP.W., BaumC.M., FiglinR.A.: Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med, 356: 115–124, 2007.
3.
EscudierB., PluzanskaA., KoralewskiP., RavaudA., BracardaS., SzczylikC., ChevreauC., FilipekM., MelicharB., BajettaE., GorbunovaB., BayJ.O., BodrogiI., Jagiello-GruszfeldA., MooreN.: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet, 370: 2103–2111, 2007.
4.
HudesG., CarducciM., TomczakP., DutcherJ., FiglinR., KapoorA, StaroslawskaE., SosmanJ., McDermottD., BodrogiI., KovacevicZ., LesovoyV., Schmidt-WolfI.G., BarbarashO., GokmenE., O'TooleT., Lustgarten MooreL., MotzerR.J.: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med, 356: 2271–2281, 2007.
5.
MotzerR.J., EscudierB., OudardS., HutsonT.E., PortaC., BracardaS., GrunwaldW., ThompsonJ.A., FiglinR.A., HollaenderN., UrbanowitzG., BergW.J., KayA., LebwohlD., RavaudA.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372: 427–429, 2008.
6.
SternbergC.N., SzczylikC., LeeE., SalmanP.V., MardiakJ., DavisI.D., PanditeL., ChenM., McCannL., HawkinsR.: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol27: abstr 5021, 2009.
7.
DudekA.Z., ZolnierekJ., DhamA., LindgrenB.R., SzczylikC.: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 115: 61–67, 2009.
8.
ProcopioG., VerzoniE., GuadalupiV., PietrantonioF., SalvioniR., NicolaiN., BajettaE.: Sequential use of sorafenib (So) followed by Sunitinib (Su) in metastatic renal cell cancer (mRCC). A single-institution experience. Proc ASCO GU, abstr 319, 2009.
9.
SosmanJ.A., FlahertyK.T., AtkinsM.B., McDermottD.F., RothenbergM.L., VermeulenW.L., HarlackerK., HsuA., WrightJ.J., PuzanovI.: Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol, 26: abstr 5011, 2008.
10.
ProcopioG., VerzoniE., BracardaS., RicciS., SaccoC., RidolfiL., PortaC., MiceliR., ZilemboN., BajettaE.: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin 2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc trial. J Clin Oncol, 27: abstr 5099, 2009.
